This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Dongen, G. A.M.S. Articles by Perk, L. R. Search for Related Content PubMed PubMed Citation Articles by van Dongen, G. A.M.S. Articles by Perk, L. R.

Cancer Imaging

Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications

^aDepartment of Otolaryngology/Head and Neck Surgery and ^bDepartment of Nuclear Medicine & PET research, VU University Medical Center, Amsterdam, The Netherlands; ^cDepartment of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands

Key Words. Immuno-PET • Positron emission tomography • Monoclonal antibodies • Scintigraphy • Molecular imaging

Correspondence: Guus A.M.S. van Dongen, Ph.D., Departments of Otolaryngology/Head and Neck Surgery, VU University Medical Center, De Boelelaan 1117, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Telephone: 0031-20-4440953; Fax: 0031-20-4443688; e-mail: gams.vandongen{at}vumc.nl

Disclosure: G.A.M.S.v.D. has performed contract work for Philips and Ablynx. No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Monoclonal antibodies (mAbs) have been approved for use as diagnostics and therapeutics in a broad range of medical indications, but especially in oncology. In addition, hundreds of new mAbs, engineered mAb fragments, and nontraditional antibody-like scaffolds directed against either validated or novel tumor targets are under development. Immuno–positron emission tomography (PET), the tracking and quantification of mAbs with PET in vivo, is an exciting novel option to improve diagnostic imaging and to guide mAb-based therapy. In this review, recent technical advances leading to a jump ahead in mAb imaging are discussed. The availability of proper positron emitters, sophisticated radiochemistry, and advanced PET and PET–computed tomography scanners is crucial in these developments. Immuno-PET might play an important future role in cancer staging, in the improvement and tailoring of therapy with existing mAbs, and in the efficient development of novel mAbs. An overview of the preclinical and first clinical immuno-PET studies is provided.

This article has been cited by other articles:

				P. K.E. Borjesson, Y. W.S. Jauw, R. de Bree, J. C. Roos, J. A. Castelijns, C. R. Leemans, G. A.M.S. van Dongen, and R. Boellaard Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients J. Nucl. Med., November 1, 2009; 50(11): 1828 - 1836. [Abstract] [Full Text] [PDF]

				E. C.F. Dijkers, J. G.W. Kosterink, A. P. Rademaker, L. R. Perk, G. A.M.S. van Dongen, J. Bart, J. R. de Jong, E. G.E. de Vries, and M. N. Lub-de Hooge Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging J. Nucl. Med., June 1, 2009; 50(6): 974 - 981. [Abstract] [Full Text] [PDF]

				A. M. Wu Antibodies and Antimatter: The Resurgence of Immuno-PET J. Nucl. Med., January 1, 2009; 50(1): 2 - 5. [Abstract] [Full Text] [PDF]

				H. J.W.L. Aerts, L. Dubois, L. Perk, P. Vermaelen, G. A.M.S. van Dongen, B. G. Wouters, and P. Lambin Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET J. Nucl. Med., January 1, 2009; 50(1): 123 - 131. [Abstract] [Full Text] [PDF]